Abstract
Tumor metastasis is a main contributor to death in cancer patients. In the last years, a new class of molecules that reduces the metastatic propensity has been identified: metastasis suppressors. These proteins regulate multiple steps in the metastatic cascade, including cell invasion, survival in the vascular and lymphatic circulation, and colonization of distant organ sites. As a consequence, they are very important therapeutic targets. This review discusses our current understanding of metastasis suppressors and how this knowledge might be useful to improve the treatment of cancer patients.
Keywords: Metastasis suppressor genes, metastatic cascade, suppressor-based therapies, cancer cell types, colonize ectopic tissue, metastatic process, Paget hypothesized, Innumerable oncogenes, amino acids, human genome, oral squamous cells, metastatic melanoma, Simpson-Golabi-Behmel syndrome (SGBS), micrometastatic tumor cells
Current Pharmaceutical Biotechnology
Title: Metastasis Suppressors: Basic and Translational Advances
Volume: 12 Issue: 11
Author(s): C. Buchanan, M. A. Lago Huvelle and M. G. Peters
Affiliation:
Keywords: Metastasis suppressor genes, metastatic cascade, suppressor-based therapies, cancer cell types, colonize ectopic tissue, metastatic process, Paget hypothesized, Innumerable oncogenes, amino acids, human genome, oral squamous cells, metastatic melanoma, Simpson-Golabi-Behmel syndrome (SGBS), micrometastatic tumor cells
Abstract: Tumor metastasis is a main contributor to death in cancer patients. In the last years, a new class of molecules that reduces the metastatic propensity has been identified: metastasis suppressors. These proteins regulate multiple steps in the metastatic cascade, including cell invasion, survival in the vascular and lymphatic circulation, and colonization of distant organ sites. As a consequence, they are very important therapeutic targets. This review discusses our current understanding of metastasis suppressors and how this knowledge might be useful to improve the treatment of cancer patients.
Export Options
About this article
Cite this article as:
Buchanan C., A. Lago Huvelle M. and G. Peters M., Metastasis Suppressors: Basic and Translational Advances, Current Pharmaceutical Biotechnology 2011; 12 (11) . https://dx.doi.org/10.2174/138920111798376914
DOI https://dx.doi.org/10.2174/138920111798376914 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticancer Effects of Cinnamaldehyde Through Inhibition of ErbB2/HSF1/LDHA
Pathway in 5637 Cell Line of Bladder Cancer
Anti-Cancer Agents in Medicinal Chemistry Application of Genetic Polymorphisms in DNA Repair in the Prediction of Cancer Susceptibility and Clinical Outcome
Current Pharmacogenomics Natural and Synthetic Retinoids in Prostate Cancer
Current Pharmaceutical Design Prediction of Disease-Related Genes Based on Hybrid Features
Current Proteomics miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents
Current Cancer Drug Targets The Use of Cytokines and Chemokines in the Cancer Immunotherapy
Recent Patents on Anti-Cancer Drug Discovery Inhibition of STAT Signalling in Bladder Cancer by Diindolylmethane - Relevance to Cell Adhesion, Migration and Proliferation
Current Cancer Drug Targets Radiobromine-Labelled Tracers for Positron Emission Tomography: Possibilities and Pitfalls
Current Radiopharmaceuticals Meet Our Editorial Board Member: Major Academic/Scientific Achievements
Current Cancer Drug Targets Editorial [Hot Topic: New Developments in the Medicinal Chemistry of Vanilloid TRPV1 and Related Receptors (Guest Editor: Arpad Szallasi)]
Current Topics in Medicinal Chemistry Bladder Cancer: Innovative Approaches Beyond the Diagnosis
Current Medicinal Chemistry Cancer “Stemness”- Regulating MicroRNAs: Role, Mechanisms and Therapeutic Potential
Current Drug Targets New Direct and Frontal Tissue Acquisition Tools for Gene Expression Analysis in Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets TRICOM Vector Based Cancer Vaccines
Current Pharmaceutical Design Vitamins for Cancer Prevention and Treatment: An Insight
Current Molecular Medicine Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Current Drug Discovery Technologies Can Medical Therapy Fix Sexual Dysfunction after Major Pelvic and Prostate Surgery and does it Work for Kidney Stones? Chemotherapy before Cystectomy, New Schemes for which Patients?
Current Drug Targets Experimental Onco-Immunology Revisited
Current Cancer Therapy Reviews The Adenine Nucleotide Translocator: A New Potential Chemotherapeutic Target
Current Drug Targets